Radioembolization for Liver Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial studies the side effects and best way to perform yttrium Y-90 radioembolization in treating patients with liver cancer that has spread to other places in the body (metastatic). Yttrium Y-90 radioembolization is a therapy that injects radioactive microspheres directly into an artery that feeds liver tumors to cut off their blood supply. Performing yttrium Y-90 radioembolization in a single session may make treatment faster, minimize patient travel, and decrease the overall cost of the procedure.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is radioembolization with Yttrium-90 safe for humans?
How is the treatment Yttrium Y 90 Resin Microspheres unique for liver cancer?
Yttrium Y 90 Resin Microspheres is a unique treatment for liver cancer because it involves radioembolization, where tiny radioactive beads are delivered directly to the liver tumors through the blood vessels, providing targeted internal radiation. This method allows for high doses of radiation to be concentrated in the tumor while minimizing exposure to surrounding healthy tissue, which is different from traditional external radiation therapies.678910
What data supports the effectiveness of the treatment Yttrium Y 90 Resin Microspheres for liver cancer?
Yttrium-90 resin microsphere radioembolization has shown potential benefits in improving survival for patients with liver cancer, particularly in those with chemotherapy-resistant liver metastases, as it may offer survival gains compared to standard care. Additionally, it has been used successfully in treating primary liver tumors, with good outcomes reported in certain patient groups.611121314
Who Is on the Research Team?
Armeen Mahvash, MD
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
This trial is for patients with liver cancer that has spread, who can understand and sign a consent form. It's suitable for those eligible for standard Y90 radioembolization treatment but not for patients where the cancer affects more than half of the liver.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients undergo diagnostic angiography and receive yttrium Y-90 radioembolization
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Yttrium Y 90 Resin Microspheres
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborator